<DOC>
	<DOC>NCT00628043</DOC>
	<brief_summary>This is a study to investigate the clinical efficacy and safety of epoetin beta 36,000 IU compared with placebo when administrated subcutaneously (s.c.) once-weekly for 12 weeks to anemic patients with lung cancer or gynecologic cancer undergoing chemotherapy.</brief_summary>
	<brief_title>Clinical Study of Epoetin Beta to Chemotherapy-Induced Anemia (CIA) Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Lung cancer or gynecologic cancer patients Undergoing platinumbased chemotherapy repeated for ≧ 2 cycles after erythropoietin (EPO) or placebo administration 8.0 g/dL ≦ hemoglobin concentration (Hb) ≦ 10.0 g/dL 20 79 years old Performance status: 0 2 No iron deficiency anemia Red blood cell transfusion within 4 weeks before treatment Erythropoietin therapy within 8 weeks before treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Cancer</keyword>
	<keyword>patients</keyword>
	<keyword>with</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>induced</keyword>
	<keyword>anemia</keyword>
</DOC>